| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CRP (174-185) targets Fcgamma receptors (CD64, CD32) on macrophages and monocytes. The full-length CRP binds to phosphocholine on microbial surfaces and activates the classical complement pathway; the fragment is believed to interact with similar immune receptors.
|
|---|---|
| ln Vitro |
CRP (174-185) significantly enhances the tumoricidal activity of human monocytes and alveolar macrophages in vitro, demonstrating potential as a biological response modifier in cancer therapy. It also induces superoxide anion release and tissue factor activity in rat macrophages.
|
| ln Vivo |
CRP (25 microg; once daily for 7 days; intravenous) protects mice from pneumococcal infection by activating complement. CRP (20 mg/kg; once daily for 3 days; intraperitoneal) induces superoxide anion release and tissue factor activity in rat macrophages.
|
| Enzyme Assay |
N/A. The activity of CRP (174-185) is typically evaluated in complement activation assays or binding assays with isolated complement components. The peptide is incubated with normal human serum (1-100 microg/mL) at 37degC for 1 hour; C3 and C4 deposition is measured by ELISA. Additionally, binding to purified human CD64 (FcgammaRI) can be assessed by surface plasmon resonance.
|
| Cell Assay |
Human monocytes or alveolar macrophages are isolated from peripheral blood and seeded at 2×10⁵ cells/well. Cells are incubated with CRP (174-185) (1-50 microg/mL) for 24-48 hours. Target tumor cells (e.g., A549 or U937) labeled with 3H-thymidine or Calcein-AM are added at an effector:target ratio of 10:1. After 4-6 hours, cell lysis is measured by gamma counter or fluorescence.
|
| Animal Protocol |
For pneumococcal infection protection, mice are injected intravenously with CRP (25 microg) daily for 7 days prior to intranasal challenge with Streptococcus pneumoniae. Survival is monitored for 14 days. For rat macrophage activation, rats receive intraperitoneal injections of CRP (20 mg/kg) once daily for 3 days; peritoneal macrophages are collected and analyzed for superoxide anion release via cytochrome c reduction assay and tissue factor activity via chromogenic assay.
|
| ADME/Pharmacokinetics |
Cannot be extracted; information not available. This peptide is derived from CRP, which typically has a plasma half-life of about 19 hours in humans and is cleared via the liver and reticuloendothelial system. For this specific peptide fragment, no dedicated PK studies have been published, but as a peptide, it likely undergoes rapid proteolytic degradation in vivo.
|
| Toxicity/Toxicokinetics |
CRP (174-185) is considered low toxicity in preclinical models at doses up to 20 mg/kg in rats, with no adverse effects reported in short-term studies. However, comprehensive toxicological evaluations including repeat-dose, genotoxicity, and carcinogenicity studies have not been conducted for this research fragment.
|
| References |
[1]. Devaraj S, et al. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis. 2009 Mar;203(1):67-74.
|
| Additional Infomation |
CRP (174-185) is also known as RS-83277. It exhibits similar activity to full-length CRP in enhancing macrophage tumoricidal activity, making it a candidate for cancer immunotherapy research. The fragment has not been approved for clinical use. Molecular formula: C62H93N13O16; molecular weight: 1276.48. It is soluble in water.
|
| Molecular Formula |
C62H93N13O16
|
|---|---|
| Molecular Weight |
1276.47933554649
|
| Exact Mass |
1275.686
|
| CAS # |
147516-85-6
|
| PubChem CID |
71308684
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
35
|
| Heavy Atom Count |
91
|
| Complexity |
2520
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O=C([C@H](CO)NC([C@H](CC1C=CC=CC=1)NC([C@@H]1CCCN1C(CNC(CNC([C@H](CC(C)C)NC([C@H](CC1C=CC(=CC=1)O)NC([C@H]([C@@H](C)CC)N)=O)=O)=O)=O)=O)=O)=O)N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CC(C)C)=O)C(C)C)=O)CC(N)=O)=O
|
| InChi Key |
KODGVWMUDZVVII-FVTMRLMCSA-N
|
| InChi Code |
InChI=1S/C62H93N13O16/c1-9-36(8)51(64)59(87)70-42(28-38-19-21-39(77)22-20-38)54(82)67-40(25-33(2)3)53(81)66-30-49(79)65-31-50(80)74-23-13-17-46(74)57(85)68-41(27-37-15-11-10-12-16-37)55(83)72-45(32-76)61(89)75-24-14-18-47(75)58(86)69-43(29-48(63)78)56(84)73-52(35(6)7)60(88)71-44(62(90)91)26-34(4)5/h10-12,15-16,19-22,33-36,40-47,51-52,76-77H,9,13-14,17-18,23-32,64H2,1-8H3,(H2,63,78)(H,65,79)(H,66,81)(H,67,82)(H,68,85)(H,69,86)(H,70,87)(H,71,88)(H,72,83)(H,73,84)(H,90,91)/t36-,40-,41-,42-,43-,44-,45-,46-,47-,51-,52-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7834 mL | 3.9170 mL | 7.8340 mL | |
| 5 mM | 0.1567 mL | 0.7834 mL | 1.5668 mL | |
| 10 mM | 0.0783 mL | 0.3917 mL | 0.7834 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
